ARCH BIOPARTNERS INC/ CA03938C1041 /
| 2024-04-19 4:44:32 PM | Chg. -0.01 | Volume | Bid4:44:32 PM | Ask4:44:32 PM | High | Low |
|---|---|---|---|---|---|---|
| 2.37CAD | -0.42% | 8,700 Turnover: 20,647 |
2.37Bid Size: 400 | 2.39Ask Size: 200 | 2.39 | 2.34 |
GlobeNewswire
04-16
St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associate...
GlobeNewswire
04-03
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...
GlobeNewswire
04-02
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire
03-18
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ ...
GlobeNewswire
03-15
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated...
GlobeNewswire
03-07
Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Car...
GlobeNewswire
02-27
Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment t...
GlobeNewswire
01-03
Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Tria...
GlobeNewswire
2023-12-21
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
2023-12-13
Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associ...
GlobeNewswire
2023-09-22
Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac...
GlobeNewswire
2022-02-14
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protoco...
GlobeNewswire
2022-02-03
Arch Scientists Publish Data on the Mechanism of Action and Efficacy of Lead Drug Candidate LSALT Pe...
GlobeNewswire
2022-01-04
Research Ethics Board approves amendment to Canadian Treatments for COVID-19 (CATCO) Trial to includ...
GlobeNewswire
2021-12-01
Arch Biopartners’ Lead Drug LSALT Peptide to Enter the Canadian Treatments for COVID-19 (CATCO) Tria...
GlobeNewswire
2021-07-14
Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease
GlobeNewswire
2021-06-10
Arch Biopartners Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediate...
GlobeNewswire
2021-05-04
Arch Biopartners Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized ...
GlobeNewswire
2021-04-15
Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin...
GlobeNewswire
2021-03-30
Turkish Ministry of Health Approves Increase in Patient Recruitment into the Phase II Trial for LSAL...
GlobeNewswire
2021-03-24
Arch Biopartners Enters Exclusive License Agreement with the University of Cincinnati for AB569 Topi...
GlobeNewswire
2021-03-16
Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Pep...
